论文部分内容阅读
目的:研究SDF1 3A基因多态性与高血压病易感性和高血压患者应用卡托普利疗效的关系。方法:运用PCR-RFLP对214名高血压患者和228名正常健康个体进行SDF1 3A基因分型。在39名不同SDF1 3A基因型的个体中, 13名高血压患者同时口服卡托普利(25 mg/d)和尼群地平(30 mg/d) , 12名高血压患者仅口服尼群地平(30 mg/d) ,所有患者连续服药8周以上,14名正常健康个体没有服任何药物。检测所有受试者的血压变化,以此评估药物的治疗效果。结果:在卡托普利和尼群地平治疗后,SDF1 3AAA+AG基因型或GG基因型的高血压患者中血浆SDF-1水平显著高于正常健康对照组(P<0.05) ;AA基因型携带者与GG基因型相比较,有较低水平的血浆总蛋白和球蛋白(P<0.05 ) ;高血压患者经卡托普利治疗后,AA +AG基因型个体的收缩压降低效果明显好于GG基因型个体(P<0.05)。结论:SDF1 3A遗传多态性可以影响中国汉族高血压患者应用卡托普利的疗效。
Objective: To investigate the relationship between SDF1 3A gene polymorphism and susceptibility to hypertension and the effect of captopril in hypertensive patients. METHODS: SDF1 3A genotyping was performed in 214 hypertensive patients and 228 healthy individuals using PCR-RFLP. Among 39 individuals with different SDF1 3A genotypes, 13 hypertensive patients were treated with both captopril (25 mg / d) and nitrendipine (30 mg / d), and 12 hypertensive patients were treated with nitrendipine (30 mg / d). All patients received continuous medication for more than 8 weeks, and 14 normal healthy subjects did not take any medication. All subjects were tested for changes in blood pressure, in order to assess the therapeutic effect of the drug. RESULTS: After treatment with captopril and nitrendipine, the plasma levels of SDF-1 in SDF1 3AAA + AG genotype or GG genotype were significantly higher than those in healthy controls (P <0.05). AA genotype There was a lower level of total plasma protein and globin (P <0.05) compared with GG genotypes. The reduction of systolic blood pressure in AA + AG genotypes was significantly better in patients with hypertension after captopril treatment GG genotype individuals (P <0.05). Conclusion: SDF1 3A genetic polymorphism can affect the efficacy of captopril in hypertensive patients of Han nationality.